Targeting the CREB pathway for memory enhancers.

Full Abstract

Today, the clinical notion of 'memory disorder' is largely synonymous with 'Alzheimer's disease.' Only 50% of all dementias are of the Alzheimer's type though, and dementias represent only the more severe of all learning/memory disorders that derive from heredity, disease, injury or age. Perhaps as many as 30 million Americans suffer some type of clinically recognized memory disorder. To date, therapeutic drugs of only one class have been approved for the treatment of Alzheimer's disease. Fortunately, basic research during the past 25 years has begun to define a 'chemistry of brain plasticity,' which is suggesting new gene targets for the discovery of memory enhancers.

Learn Faster Today Improve your study skills

Author information

Author/s: Tully, Tim (T); Bourtchouladze, Rusiko (R); Scott, Rod (R); Tallman, John (J);

Affiliation: Helicon Therapeutics, Inc., One Bioscience Park Drive, Farmingdale, New York 11743, USA.

Journal and publication information

Publication Type: Journal Article; Review

Journal: Nature reviews. Drug discovery (Nat Rev Drug Discov), published in England. (Language: eng)

Reference: 2003-Apr; vol 2 (issue 4) : pp 267-77

Dates: Created 2003/04/01; Completed 2003/04/23; Revised 2005/11/17;

PMID: 12669026, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Alzheimer Disease - drug therapy; metabolism
Animals
Brain - drug effects; metabolism
Cyclic AMP Response Element-Binding Protein - metabolism
Drug Delivery Systems

Drug Evaluation, Preclinical
Humans
Memory - drug effects
Models, Animal
Neuroprotective Agents - therapeutic use

Associated Chemicals: Cyclic AMP Response Element-Binding Protein (0) ; Neuroprotective Agents (0)

These are the highest related articles currently in the database:

See 100+ related articles.